Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration
Tuesday, February 14, 2023
Sentia Medical Sciences announced that they have extended a research collaboration with Neurocrine Biosciences to discover novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialise medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA) axis modulated diseases.
This collaboration focuses on the discovery and development of novel peptide therapeutics to address HPA-driven diseases.
Under the terms of the research collaboration extension, Sentia and Neurocrine will continue to work together to discover novel peptide antagonists targeting CRF and advance into development candidate stage, after which Neurocrine will be solely responsible for all further development, manufacturing, regulatory and commercial activities.
